Company’s focus on advancing first-in-class oral degraders with biologics-like activity to address areas of significant patient need and market potential STAT6 oral degrader KT-621, with ...
"How do we engage with people that we are supposed to be serving?" Dr. Frances Lund, director of the Immunology Institute, said at the Aspen Ideas Health in Aspen, CO on June 25, 2025. She was invited ...
See Response to 'Class II essential for CD4 survival' by Jeffrey R. Dorfman and the Concentration of MHC class II molecules in lipid rafts facilitates antigen presentation by Jeffrey R. Dorfman.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback